NASDAQ:CRBP - Corbus Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$5.90 -0.02 (-0.34 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$5.90
Today's Range$5.85 - $6.00
52-Week Range$5.05 - $9.95
Volume203,557 shs
Average Volume801,864 shs
Market Capitalization$345.71 million
P/E Ratio-9.08
Dividend YieldN/A
Beta2.23

About Corbus Pharmaceuticals (NASDAQ:CRBP)

Corbus Pharmaceuticals logoCorbus Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, focuses on the development and commercialization of various therapeutic products to treat inflammatory and fibrotic diseases. The company's lead product candidate is lenabasum, a synthetic oral endocannabinoid-mimetic drug that is in Phase III clinical trials for the treatment of systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus diseases. Corbus Pharmaceuticals Holdings, Inc. was founded in 2009 and is based in Norwood, Massachusetts.

Receive CRBP News and Ratings via Email

Sign-up to receive the latest news and ratings for CRBP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CRBP
CUSIPN/A
Phone617-963-0100

Debt

Debt-to-Equity RatioN/A
Current Ratio7.25
Quick Ratio7.25

Price-To-Earnings

Trailing P/E Ratio-9.08
Forward P/E Ratio-7.28
P/E GrowthN/A

Sales & Book Value

Annual Sales$2.44 million
Price / Sales138.17
Cash FlowN/A
Price / CashN/A
Book Value$1.15 per share
Price / Book5.13

Profitability

EPS (Most Recent Fiscal Year)($0.65)
Net Income$-32,420,000.00
Net Margins-1,040.41%
Return on Equity-76.01%
Return on Assets-64.57%

Miscellaneous

Employees47
Outstanding Shares57,140,000

Corbus Pharmaceuticals (NASDAQ:CRBP) Frequently Asked Questions

What is Corbus Pharmaceuticals' stock symbol?

Corbus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRBP."

How were Corbus Pharmaceuticals' earnings last quarter?

Corbus Pharmaceuticals (NASDAQ:CRBP) issued its earnings results on Thursday, May, 10th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing the Zacks' consensus estimate of ($0.10) by $0.11. The biopharmaceutical company earned $0.95 million during the quarter, compared to analyst estimates of $6.25 million. Corbus Pharmaceuticals had a negative net margin of 1,040.41% and a negative return on equity of 76.01%. View Corbus Pharmaceuticals' Earnings History.

What price target have analysts set for CRBP?

3 analysts have issued twelve-month price objectives for Corbus Pharmaceuticals' shares. Their predictions range from $20.00 to $32.00. On average, they expect Corbus Pharmaceuticals' stock price to reach $25.3333 in the next twelve months. View Analyst Ratings for Corbus Pharmaceuticals.

Who are some of Corbus Pharmaceuticals' key competitors?

Who are Corbus Pharmaceuticals' key executives?

Corbus Pharmaceuticals' management team includes the folowing people:
  • Dr. Yuval Cohen, CEO & Director (Age 43)
  • Dr. Mark A. Tepper Ph.D., Co-Founder, Pres & Chief Scientific Officer (Age 61)
  • Dr. Barbara White M.D., Chief Medical Officer (Age 68)
  • Mr. Sean F. Moran CPA, MBA, CFO & Principal Accounting Officer (Age 60)
  • Scott Constantine M.S., Director of Clinical Research & Operations

Has Corbus Pharmaceuticals been receiving favorable news coverage?

News articles about CRBP stock have been trending positive this week, Accern reports. Accern ranks the sentiment of news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Corbus Pharmaceuticals earned a daily sentiment score of 0.36 on Accern's scale. They also assigned news stories about the biopharmaceutical company an impact score of 47.59 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

Who are Corbus Pharmaceuticals' major shareholders?

Corbus Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.39%), ETF Managers Group LLC (4.30%), IFP Advisors Inc (2.35%), Allianz Asset Management GmbH (0.24%), Allianz Asset Management GmbH (0.24%) and Royal Bank of Canada (0.09%). Company insiders that own Corbus Pharmaceuticals stock include Alan F Holmer, Barbara White, David P Hochman, Sean F Moran and Yuval Cohen. View Institutional Ownership Trends for Corbus Pharmaceuticals.

Which institutional investors are buying Corbus Pharmaceuticals stock?

CRBP stock was acquired by a variety of institutional investors in the last quarter, including ETF Managers Group LLC, IFP Advisors Inc, BlackRock Inc., Royal Bank of Canada, Barclays PLC, Allianz Asset Management GmbH, Allianz Asset Management GmbH and Cambridge Investment Research Advisors Inc.. Company insiders that have bought Corbus Pharmaceuticals stock in the last two years include Alan F Holmer, Barbara White, David P Hochman, Sean F Moran and Yuval Cohen. View Insider Buying and Selling for Corbus Pharmaceuticals.

How do I buy shares of Corbus Pharmaceuticals?

Shares of CRBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Corbus Pharmaceuticals' stock price today?

One share of CRBP stock can currently be purchased for approximately $5.90.

How big of a company is Corbus Pharmaceuticals?

Corbus Pharmaceuticals has a market capitalization of $345.71 million and generates $2.44 million in revenue each year. The biopharmaceutical company earns $-32,420,000.00 in net income (profit) each year or ($0.65) on an earnings per share basis. Corbus Pharmaceuticals employs 47 workers across the globe.

How can I contact Corbus Pharmaceuticals?

Corbus Pharmaceuticals' mailing address is 500 River Ridge Drive, Norwood MA, 02062. The biopharmaceutical company can be reached via phone at 617-963-0100 or via email at [email protected]


MarketBeat Community Rating for Corbus Pharmaceuticals (CRBP)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  194 (Vote Outperform)
Underperform Votes:  97 (Vote Underperform)
Total Votes:  291
MarketBeat's community ratings are surveys of what our community members think about Corbus Pharmaceuticals and other stocks. Vote "Outperform" if you believe CRBP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRBP will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Corbus Pharmaceuticals (NASDAQ:CRBP) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
3 Wall Street analysts have issued ratings and price targets for Corbus Pharmaceuticals in the last 12 months. Their average twelve-month price target is $25.3333, suggesting that the stock has a possible upside of 329.38%. The high price target for CRBP is $32.00 and the low price target for CRBP is $20.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $25.3333$25.3333$24.75$20.75
Price Target Upside: 329.38% upside272.55% upside211.32% upside202.92% upside

Corbus Pharmaceuticals (NASDAQ:CRBP) Consensus Price Target History

Price Target History for Corbus Pharmaceuticals (NASDAQ:CRBP)

Corbus Pharmaceuticals (NASDAQ:CRBP) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/10/2018Cantor FitzgeraldSet Price TargetBuy$32.00HighView Rating Details
3/13/2018Noble FinancialReiterated RatingBuyMediumView Rating Details
1/19/2018Raymond JamesInitiated CoverageOutperform ➝ Outperform$24.00HighView Rating Details
4/3/2017JMP SecuritiesReiterated RatingOutperform$20.00 ➝ $27.00LowView Rating Details
11/30/2016AegisReiterated RatingBuy$12.00N/AView Rating Details
(Data available from 5/26/2016 forward)

Earnings

Corbus Pharmaceuticals (NASDAQ:CRBP) Earnings History and Estimates Chart

Earnings by Quarter for Corbus Pharmaceuticals (NASDAQ:CRBP)

Corbus Pharmaceuticals (NASDAQ:CRBP) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.81 EPS
Next Year EPS Consensus Estimate: $-0.92 EPS

Corbus Pharmaceuticals (NASDAQ CRBP) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2018Q1 2018($0.10)($0.21)$6.25 million$0.95 millionViewN/AView Earnings Details
3/12/2018Q4 2017($0.1550)($0.20)ViewN/AView Earnings Details
11/8/2017Q3 2017($0.16)($0.14)$0.80 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.19)($0.15)$0.50 million$0.35 millionViewN/AView Earnings Details
5/9/2017Q1 2017($0.16)($0.16)$2.50 million$1.29 millionViewN/AView Earnings Details
3/9/2017Q4 2016($0.1220)($0.18)$1.50 million$0.38 millionViewN/AView Earnings Details
11/10/2016Q3 2016($0.10)($0.12)$1.00 million$0.74 millionViewN/AView Earnings Details
8/15/2016Q216($0.08)($0.11)$1.25 million$0.40 millionViewN/AView Earnings Details
5/16/2016Q116($0.08)($0.08)$0.40 millionViewN/AView Earnings Details
3/29/2016Q4 2015($0.06)($0.06)$1.25 million$0.36 millionViewN/AView Earnings Details
11/10/2015Q315($0.08)($0.06)$0.17 millionViewN/AView Earnings Details
8/13/2015Q2 2015($0.06)($0.10)$0.11 millionViewN/AView Earnings Details
5/13/2015Q1 2015($0.05)($0.06)ViewN/AView Earnings Details
2/10/2015Q4 2014($0.03)($0.06)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Corbus Pharmaceuticals (NASDAQ:CRBP) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Corbus Pharmaceuticals (NASDAQ CRBP) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 11.90%
Institutional Ownership Percentage: 42.08%
Insider Trading History for Corbus Pharmaceuticals (NASDAQ:CRBP)
Institutional Ownership by Quarter for Corbus Pharmaceuticals (NASDAQ:CRBP)

Corbus Pharmaceuticals (NASDAQ CRBP) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/15/2018Barbara WhiteInsiderBuy2,586$5.87$15,179.82179,521View SEC Filing  
5/15/2018Sean F MoranCFOBuy4,000$5.77$23,080.00348,010View SEC Filing  
5/15/2018Yuval CohenCEOBuy1,725$5.85$10,091.2561,660View SEC Filing  
5/14/2018David P HochmanDirectorBuy5,000$5.48$27,400.00459,500View SEC Filing  
3/14/2018Barbara WhiteInsiderBuy2,885$6.89$19,877.65176,935View SEC Filing  
3/14/2018David P HochmanDirectorBuy5,000$6.67$33,350.00459,500View SEC Filing  
3/14/2018Sean F MoranCFOBuy3,100$6.60$20,460.00344,010View SEC Filing  
3/14/2018Yuval CohenCEOBuy1,160$6.89$7,992.4059,935View SEC Filing  
11/15/2017David P HochmanDirectorBuy5,000$6.55$32,750.00459,500View SEC Filing  
11/13/2017David P HochmanDirectorBuy5,000$6.90$34,500.00View SEC Filing  
11/10/2017Barbara WhiteInsiderBuy2,836$7.00$19,852.00174,050View SEC Filing  
11/10/2017David P HochmanDirectorBuy10,000$7.08$70,800.00459,500View SEC Filing  
11/10/2017Sean F MoranCFOBuy1,500$7.04$10,560.00340,910View SEC Filing  
11/10/2017Yuval CohenCEOBuy1,000$7.17$7,170.0058,775View SEC Filing  
8/11/2017Barbara WhiteInsiderBuy2,479$6.05$14,997.95171,214View SEC Filing  
8/11/2017Sean F MoranCFOBuy2,500$5.91$14,775.00339,410View SEC Filing  
8/11/2017Yuval CohenCEOBuy1,695$6.00$10,170.0057,775View SEC Filing  
5/11/2017Barbara WhiteInsiderBuy2,435$6.12$14,902.20168,735View SEC Filing  
5/11/2017David P HochmanDirectorBuy3,400$6.18$21,012.00459,500View SEC Filing  
5/11/2017Sean F MoranCFOBuy3,300$6.14$20,262.00336,910View SEC Filing  
5/11/2017Yuval CohenCEOBuy3,250$6.01$19,532.5056,080View SEC Filing  
3/17/2017Barbara WhiteInsiderBuy4,233$9.49$40,171.17166,300View SEC Filing  
3/13/2017Sean F MoranCFOBuy2,000$9.60$19,200.00333,610View SEC Filing  
12/2/2016Sean F MoranCFOBuy1,500$7.20$10,800.00331,610View SEC Filing  
11/22/2016Alan F HolmerDirectorBuy1,000$7.49$7,490.0022,000View SEC Filing  
11/22/2016Yuval CohenCEOBuy1,340$7.64$10,237.6012,830View SEC Filing  
11/18/2016David P HochmanDirectorBuy10,000$7.00$70,000.00456,100View SEC Filing  
9/8/2016Sean F MoranCFOBuy30,800$5.12$157,696.00330,110View SEC Filing  
8/26/2016Sean F MoranCFOBuy17,900$3.92$70,168.00299,310View SEC Filing  
8/22/2016David P HochmanDirectorBuy1,800$3.77$6,786.00456,100View SEC Filing  
8/18/2016Sean F MoranCFOBuy148,960$3.32$494,547.20216,410View SEC Filing  
8/17/2016Barbara WhiteInsiderBuy38,000$3.15$119,700.00161,067View SEC Filing  
6/8/2016Barbara WhiteInsiderBuy1,935$3.10$5,998.50123,067View SEC Filing  
6/6/2016Yuval CohenCEOBuy1,500$3.34$5,010.0011,490View SEC Filing  
6/1/2016Barbara WhiteInsiderBuy2,570$3.52$9,046.40121,132View SEC Filing  
5/19/2016Sean F MoranCFOBuy27,250$2.37$64,582.50132,450View SEC Filing  
5/18/2016Sean F MoranCFOBuy30,000$2.39$71,700.00105,250View SEC Filing  
5/18/2016Yuval CohenCEOBuy2,125$2.40$5,100.009,990View SEC Filing  
12/11/2015Sean F MoranCFOBuy1,000$1.56$1,560.0075,250View SEC Filing  
12/10/2015Sean F MoranCFOBuy1,000$1.61$1,610.0074,250View SEC Filing  
12/9/2015Sean F MoranCFOBuy1,000$1.67$1,670.0073,250View SEC Filing  
12/8/2015Sean F MoranCFOBuy1,000$1.68$1,680.0072,250View SEC Filing  
12/7/2015Sean F MoranCFOBuy1,000$1.69$1,690.0071,250View SEC Filing  
12/4/2015Sean F MoranCFOBuy1,000$1.72$1,720.0070,250View SEC Filing  
12/2/2015Sean F MoranCFOBuy1,000$1.79$1,790.0069,250View SEC Filing  
11/24/2015Sean F MoranCFOBuy1,500$1.78$2,670.0068,250View SEC Filing  
11/20/2015Sean F MoranCFOBuy1,500$1.70$2,550.0066,750View SEC Filing  
11/19/2015Barbara WhiteInsiderBuy4,000$1.67$6,680.00118,562View SEC Filing  
11/18/2015Sean F MoranCFOBuy1,500$1.71$2,565.0065,250View SEC Filing  
11/17/2015Sean F MoranCFOBuy1,500$1.72$2,580.0063,750View SEC Filing  
11/16/2015Sean F MoranCFOBuy2,000$1.69$3,380.0062,250View SEC Filing  
9/16/2015Sean F MoranCFOBuy5,000$2.12$10,600.0060,250View SEC Filing  
9/15/2015Sean F MoranCFOBuy5,000$2.14$10,700.0055,250View SEC Filing  
9/14/2015Sean F MoranCFOBuy5,000$1.96$9,800.0050,250View SEC Filing  
9/11/2015Sean F MoranCFOBuy5,000$1.85$9,250.0045,250View SEC Filing  
9/3/2015Barbara WhiteInsiderBuy10,000$1.84$18,400.00113,862View SEC Filing  
8/25/2015Barbara WhiteInsiderBuy6,000$1.87$11,220.00103,862View SEC Filing  
8/21/2015Barbara WhiteInsiderBuy10,000$2.05$20,500.0097,862View SEC Filing  
8/21/2015Sean F MoranCFOBuy1,400$2.06$2,884.0040,250View SEC Filing  
8/19/2015Sumner BursteinMajor ShareholderSell200,000$3.04$608,000.003,594,846View SEC Filing  
8/18/2015Barbara WhiteinsiderBuy20,000$1.90$38,000.0087,862View SEC Filing  
8/18/2015Renu GuptaDirectorBuy10,000$1.89$18,900.0015,000View SEC Filing  
8/18/2015Sean F MoranCFOBuy1,000$1.92$1,920.0038,850View SEC Filing  
8/17/2015Avery W CatlinDirectorBuy11,788$1.94$22,868.72View SEC Filing  
8/17/2015Yuval CohenCEOBuy2,100$1.92$4,032.00View SEC Filing  
7/15/2015Sumner BursteinMajor ShareholderSell30,000$2.82$84,600.00View SEC Filing  
6/15/2015Barbara WhiteInsiderBuy2,250$3.25$7,312.50View SEC Filing  
6/12/2015Barbara WhiteInsiderBuy6,000$3.00$18,000.00View SEC Filing  
6/9/2015Avery W CatlinDirectorBuy20,000$3.10$62,000.00View SEC Filing  
6/9/2015Sean F MoranCFOBuy6,500$3.00$19,500.00View SEC Filing  
12/18/2014Sean F MoranCFOBuy18,800$3.36$63,168.00View SEC Filing  
12/17/2014Sean F MoranCFOBuy2,850$3.46$9,861.00View SEC Filing  
12/11/2014Sean F MoranCFOBuy1,000$3.98$3,980.00View SEC Filing  
12/9/2014Sean F MoranCFOBuy1,700$3.98$6,766.00View SEC Filing  
12/4/2014Barbara WhiteInsiderBuy3,300$3.00$9,900.00View SEC Filing  
12/4/2014David P HochmanDirectorBuy1,300$3.05$3,965.00View SEC Filing  
12/4/2014Sean F MoranCFOBuy2,000$3.20$6,400.00View SEC Filing  
12/3/2014Yuval CohenCEOBuy1,000$3.20$3,200.00View SEC Filing  
12/2/2014Sean F MoranCFOBuy1,000$3.03$3,030.00View SEC Filing  
12/1/2014Barbara WhiteInsiderBuy16,448$3.00$49,344.00View SEC Filing  
11/28/2014Barbara WhiteInsiderBuy19,933$3.00$59,799.00View SEC Filing  
11/26/2014Barbara WhiteInsiderBuy13,400$3.00$40,200.00View SEC Filing  
11/26/2014Sean F MoranCFOBuy1,000$3.05$3,050.00View SEC Filing  
11/25/2014Mark TepperInsiderBuy2,000$3.05$6,100.00View SEC Filing  
11/25/2014Sean F MoranCFOBuy3,000$3.05$9,150.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Corbus Pharmaceuticals (NASDAQ CRBP) News Headlines

Source:
DateHeadline
Corbus Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare ConferenceCorbus Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference
finance.yahoo.com - May 24 at 10:18 AM
Cantor Fitzgerald Comments on Corbus Pharmaceuticals FY2018 Earnings (CRBP)Cantor Fitzgerald Comments on Corbus Pharmaceuticals' FY2018 Earnings (CRBP)
www.americanbankingnews.com - May 24 at 8:38 AM
Corbus Pharmaceuticals Adds Two Key Executives to Lead its Regulatory and CMC OperationsCorbus Pharmaceuticals Adds Two Key Executives to Lead its Regulatory and CMC Operations
finance.yahoo.com - May 22 at 9:55 AM
Form 4 Corbus Pharmaceuticals For: May 15 Filed by: Cohen YuvalForm 4 Corbus Pharmaceuticals For: May 15 Filed by: Cohen Yuval
www.streetinsider.com - May 17 at 3:52 PM
Barbara White Acquires 2,586 Shares of Corbus Pharmaceuticals (CRBP) StockBarbara White Acquires 2,586 Shares of Corbus Pharmaceuticals (CRBP) Stock
www.americanbankingnews.com - May 16 at 4:41 PM
Insider Buying: Corbus Pharmaceuticals (CRBP) CEO Buys 1,725 Shares of StockInsider Buying: Corbus Pharmaceuticals (CRBP) CEO Buys 1,725 Shares of Stock
www.americanbankingnews.com - May 16 at 10:18 AM
David P. Hochman Buys 5,000 Shares of Corbus Pharmaceuticals (CRBP) StockDavid P. Hochman Buys 5,000 Shares of Corbus Pharmaceuticals (CRBP) Stock
www.americanbankingnews.com - May 15 at 4:45 PM
Corbus Pharmaceuticals (CRBP) CFO Acquires $23,080.00 in StockCorbus Pharmaceuticals (CRBP) CFO Acquires $23,080.00 in Stock
www.americanbankingnews.com - May 15 at 4:45 PM
Corbus: Revisiting This ~$5 Biotech ConcernCorbus: Revisiting This ~$5 Biotech Concern
seekingalpha.com - May 15 at 10:49 AM
Corbus Pharmaceuticals Announces Acceptance of Three Abstracts for Presentation at EULAR 2018 Annual MeetingCorbus Pharmaceuticals Announces Acceptance of Three Abstracts for Presentation at EULAR 2018 Annual Meeting
finance.yahoo.com - May 15 at 10:49 AM
Should Corbus Pharmaceuticals Holdings Inc’s (NASDAQ:CRBP) Recent Earnings Decline Worry You?Should Corbus Pharmaceuticals Holdings Inc’s (NASDAQ:CRBP) Recent Earnings Decline Worry You?
finance.yahoo.com - May 12 at 3:54 PM
Corbus Pharmaceuticals (CRBP) Posts  Earnings Results, Misses Expectations By $0.11 EPSCorbus Pharmaceuticals (CRBP) Posts Earnings Results, Misses Expectations By $0.11 EPS
www.americanbankingnews.com - May 11 at 11:32 PM
Corbus Pharmaceuticals (CRBP) Stock Rating Lowered by BidaskClubCorbus Pharmaceuticals (CRBP) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - May 11 at 9:13 PM
Cantor Fitzgerald Analysts Give Corbus Pharmaceuticals (CRBP) a $32.00 Price TargetCantor Fitzgerald Analysts Give Corbus Pharmaceuticals (CRBP) a $32.00 Price Target
www.americanbankingnews.com - May 10 at 3:23 PM
Corbus Pharmaceuticals misses by $0.07, misses on revenueCorbus Pharmaceuticals misses by $0.07, misses on revenue
seekingalpha.com - May 10 at 10:24 AM
Corbus Pharmaceuticals: 1Q Earnings SnapshotCorbus Pharmaceuticals: 1Q Earnings Snapshot
finance.yahoo.com - May 10 at 10:24 AM
Corbus Pharmaceuticals Reports 2018 First Quarter Financial Results and Provides Business UpdateCorbus Pharmaceuticals Reports 2018 First Quarter Financial Results and Provides Business Update
finance.yahoo.com - May 10 at 10:24 AM
What Should We Expect From Corbus Pharmaceuticals Holdings Inc’s (NASDAQ:CRBP) Earnings In The Next Couple Of Years?What Should We Expect From Corbus Pharmaceuticals Holdings Inc’s (NASDAQ:CRBP) Earnings In The Next Couple Of Years?
finance.yahoo.com - April 28 at 10:44 AM
Corbus Pharmaceuticals Presents Big Risk And Big RewardCorbus Pharmaceuticals Presents Big Risk And Big Reward
seekingalpha.com - April 26 at 10:05 AM
Corbus Pharmaceuticals to Present at the Deutsche Bank 43rd Annual Health Care ConferenceCorbus Pharmaceuticals to Present at the Deutsche Bank 43rd Annual Health Care Conference
finance.yahoo.com - April 26 at 10:05 AM
3 Most Heavily Shorted Marijuana Stocks -- Are the Naysayers Wrong?3 Most Heavily Shorted Marijuana Stocks -- Are the Naysayers Wrong?
finance.yahoo.com - April 1 at 10:17 AM
Corbus Pharmaceuticals (CRBP) PT Raised to $20.00Corbus Pharmaceuticals (CRBP) PT Raised to $20.00
www.americanbankingnews.com - April 1 at 9:40 AM
TESARO (TSRO) and Corbus Pharmaceuticals (CRBP) Financial ReviewTESARO (TSRO) and Corbus Pharmaceuticals (CRBP) Financial Review
www.americanbankingnews.com - March 19 at 2:08 PM
Corbus Pharmaceuticals (CRBP) Given a $32.00 Price Target by Cantor Fitzgerald AnalystsCorbus Pharmaceuticals (CRBP) Given a $32.00 Price Target by Cantor Fitzgerald Analysts
www.americanbankingnews.com - March 18 at 12:27 PM
Corbus Pharmaceuticals (CRBP) Downgraded by BidaskClub to "Sell"Corbus Pharmaceuticals (CRBP) Downgraded by BidaskClub to "Sell"
www.americanbankingnews.com - March 17 at 6:44 PM
FY2018 EPS Estimates for Corbus Pharmaceuticals Holdings Inc Cut by Cantor Fitzgerald (CRBP)FY2018 EPS Estimates for Corbus Pharmaceuticals Holdings Inc Cut by Cantor Fitzgerald (CRBP)
www.americanbankingnews.com - March 16 at 10:48 AM
Corbus Pharmaceuticals (CRBP) Presents At 38th Annual Cowen And Company Healthcare Conference - SlideshowCorbus Pharmaceuticals (CRBP) Presents At 38th Annual Cowen And Company Healthcare Conference - Slideshow
seekingalpha.com - March 15 at 3:55 PM
Corbus Pharmaceuticals Holdings Inc (CRBP) Insider Barbara White Buys 2,885 SharesCorbus Pharmaceuticals Holdings Inc (CRBP) Insider Barbara White Buys 2,885 Shares
www.americanbankingnews.com - March 15 at 1:20 PM
Insider Buying: Corbus Pharmaceuticals Holdings Inc (CRBP) Director Acquires 5,000 Shares of StockInsider Buying: Corbus Pharmaceuticals Holdings Inc (CRBP) Director Acquires 5,000 Shares of Stock
www.americanbankingnews.com - March 15 at 1:20 PM
Noble Financial Reaffirms "Buy" Rating for Corbus Pharmaceuticals (CRBP)Noble Financial Reaffirms "Buy" Rating for Corbus Pharmaceuticals (CRBP)
www.americanbankingnews.com - March 14 at 7:16 PM
Insider Buying: Corbus Pharmaceuticals Holdings Inc (CRBP) CFO Purchases 3,100 Shares of StockInsider Buying: Corbus Pharmaceuticals Holdings Inc (CRBP) CFO Purchases 3,100 Shares of Stock
www.americanbankingnews.com - March 14 at 1:35 PM
Corbus Wounded in FY17, Shares SinkCorbus Wounded in FY17, Shares Sink
www.baystreet.ca - March 13 at 11:45 AM
Corbus Pharmaceuticals Reports 2017 Financial Results and Provides Clinical UpdateCorbus Pharmaceuticals Reports 2017 Financial Results and Provides Clinical Update
finance.yahoo.com - March 13 at 11:45 AM
Corbus Pharmaceuticals (CRBP) Issues  Earnings ResultsCorbus Pharmaceuticals (CRBP) Issues Earnings Results
www.americanbankingnews.com - March 13 at 11:12 AM
Corbus Pharmaceuticals Holdings Inc (CRBP) Receives Average Recommendation of "Buy" from BrokeragesCorbus Pharmaceuticals Holdings Inc (CRBP) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - March 10 at 9:37 AM
Corbus Pharmaceuticals (CRBP) Upgraded to Hold by ValuEngineCorbus Pharmaceuticals (CRBP) Upgraded to Hold by ValuEngine
www.americanbankingnews.com - March 4 at 8:56 PM
Corbus Pharmaceuticals to Present at the Cowen & Co. 38th Annual Health Care ConferenceCorbus Pharmaceuticals to Present at the Cowen & Co. 38th Annual Health Care Conference
finance.yahoo.com - March 2 at 10:27 AM
Corbus Pharmaceuticals Holdings Inc (CRBP) Stake Lessened by Raymond James Financial Services Advisors Inc.Corbus Pharmaceuticals Holdings Inc (CRBP) Stake Lessened by Raymond James Financial Services Advisors Inc.
www.americanbankingnews.com - March 2 at 8:21 AM
What Is Corbus Pharmaceuticals Holdings Inc’s (NASDAQ:CRBP) Financial Position?What Is Corbus Pharmaceuticals Holdings Inc’s (NASDAQ:CRBP) Financial Position?
finance.yahoo.com - February 22 at 10:14 AM
Corbus Pharmaceuticals Announces Publication Demonstrating Lenabasum as First Drug to Stimulate Resolution of Innate Immune Responses in a Clinical ModelCorbus Pharmaceuticals Announces Publication Demonstrating Lenabasum as First Drug to Stimulate Resolution of Innate Immune Responses in a Clinical Model
finance.yahoo.com - February 15 at 3:55 PM
Corbus Pharmaceuticals to Present at the 2018 RBC Capital Markets Global Healthcare ConferenceCorbus Pharmaceuticals to Present at the 2018 RBC Capital Markets Global Healthcare Conference
finance.yahoo.com - February 14 at 3:21 PM
Corbus Pharmaceuticals Holdings Inc (CRBP) Given Consensus Rating of "Buy" by BrokeragesCorbus Pharmaceuticals Holdings Inc (CRBP) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - February 13 at 9:22 AM
Corbus Pharmaceuticals to Present at the 7th Annual LEERINK Partners Global Healthcare ConferenceCorbus Pharmaceuticals to Present at the 7th Annual LEERINK Partners Global Healthcare Conference
finance.yahoo.com - February 6 at 3:19 PM
Corbus Pharmaceuticals (CRBP) Cut to Hold at BidaskClubCorbus Pharmaceuticals (CRBP) Cut to Hold at BidaskClub
www.americanbankingnews.com - February 3 at 8:46 PM
Corbus Is A Buy, But Not For Cystic Fibrosis - Seeking AlphaCorbus Is A Buy, But Not For Cystic Fibrosis - Seeking Alpha
seekingalpha.com - February 2 at 5:43 AM
Corbus Pharma awarded $25M from CF Foundation to support development of lenabasum; shares up 3% premarket - Seeking AlphaCorbus Pharma awarded $25M from CF Foundation to support development of lenabasum; shares up 3% premarket - Seeking Alpha
seekingalpha.com - February 1 at 3:18 PM
Wired News – Cystic Fibrosis Foundation Gets Development Award to Support Corbus Pharma’s Phase-2b Clinical Study of LenabasumWired News – Cystic Fibrosis Foundation Gets Development Award to Support Corbus Pharma’s Phase-2b Clinical Study of Lenabasum
finance.yahoo.com - February 1 at 3:18 PM
Corbus Pharma (CRBP) Reports Agreement with FDA on Phase 2b Cystic Fibrosis Study Design with Pulmonary ... - StreetInsider.comCorbus Pharma (CRBP) Reports Agreement with FDA on Phase 2b Cystic Fibrosis Study Design with Pulmonary ... - StreetInsider.com
www.streetinsider.com - January 31 at 5:49 AM
Pre-Open Movers 01/30: (SMRT) (CALD) (CRBP) Higher; (SMG) (MXIMI) (ESRX) (UNH) Lower (more...) - StreetInsider.comPre-Open Movers 01/30: (SMRT) (CALD) (CRBP) Higher; (SMG) (MXIMI) (ESRX) (UNH) Lower (more...) - StreetInsider.com
www.streetinsider.com - January 30 at 3:18 PM
Corbus Pharmaceuticals Receives $25 Million Development Award from the Cystic Fibrosis Foundation to Support ... - BenzingaCorbus Pharmaceuticals Receives $25 Million Development Award from the Cystic Fibrosis Foundation to Support ... - Benzinga
www.benzinga.com - January 30 at 3:18 PM

SEC Filings

Corbus Pharmaceuticals (NASDAQ:CRBP) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Corbus Pharmaceuticals (NASDAQ:CRBP) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Corbus Pharmaceuticals (NASDAQ CRBP) Stock Chart for Saturday, May, 26, 2018

Loading chart…

This page was last updated on 5/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.